Entinostat Doesn ' t Overcome Endocrine Resistance in Breast Cancer Entinostat Doesn ' t Overcome Endocrine Resistance in Breast Cancer

The histone deacetylase inhibitor entinostat failed to overcome resistance to endocrine therapy in hormone receptor –positive, HER2-negative, advanced breast cancer in a phase 3 trial.Medscape Medical News

Source: Medscape Medical News Headlines - January 13, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news